104 related articles for article (PubMed ID: 38715164)
1. Cinobufotalin Capsule Combined with Zoledronic Acid in the Treatment of Pain Symptoms and Clinical Efficacy in Prostate Cancer Patients with Bone Metastases: A Retrospective Study.
Zhang F; Dong Y; Chen F; Niu M; Liu Z; Wang C
Arch Esp Urol; 2024 Apr; 77(3):242-248. PubMed ID: 38715164
[TBL] [Abstract][Full Text] [Related]
2. Zoledronic acid combined with chemotherapy in non-small cell lung cancer with bone metastasis.
Zhang J; Wang LYJGJZYPM
J BUON; 2021; 26(3):830-836. PubMed ID: 34268942
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Jakob T; Tesfamariam YM; Macherey S; Kuhr K; Adams A; Monsef I; Heidenreich A; Skoetz N
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013020. PubMed ID: 33270906
[TBL] [Abstract][Full Text] [Related]
4. Clinical effect of intravenous infusion of zoledronic acid combined with oral medication of cinobufagin in the treatment of metastatic bone tumors.
Wang T; Zhang L; Han L; Liu X; Zhang H; Zhang J; Yu H
Pak J Pharm Sci; 2018 Jul; 31(4(Special)):1609-1612. PubMed ID: 30203746
[TBL] [Abstract][Full Text] [Related]
5. Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS).
Wirth M; Tammela T; Cicalese V; Gomez Veiga F; Delaere K; Miller K; Tubaro A; Schulze M; Debruyne F; Huland H; Patel A; Lecouvet F; Caris C; Witjes W
Eur Urol; 2015 Mar; 67(3):482-91. PubMed ID: 24630685
[TBL] [Abstract][Full Text] [Related]
6. Additive effect of zoledronic acid on serum prostate-specific antigen changes for hormone-sensitive prostate cancer patients with bone metastasis treated by combined androgen blockade.
Kamiya N; Suzuki H; Endo T; Takano M; Yano M; Naoi M; Nishimi D; Kawamura K; Imamoto T; Ichikawa T
Int J Urol; 2012 Feb; 19(2):169-73. PubMed ID: 22126137
[TBL] [Abstract][Full Text] [Related]
7. Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance).
Smith MR; Halabi S; Ryan CJ; Hussain A; Vogelzang N; Stadler W; Hauke RJ; Monk JP; Saylor P; Bhoopalam N; Saad F; Sanford B; Kelly WK; Morris M; Small EJ
J Clin Oncol; 2014 Apr; 32(11):1143-50. PubMed ID: 24590644
[TBL] [Abstract][Full Text] [Related]
8. Comparison between zoledronic acid and clodronate in the treatment of prostate cancer patients with bone metastases.
Wang F; Chen W; Chen H; Mo L; Jin H; Yu Z; Li C; Liu Q; Duan F; Weng Z
Med Oncol; 2013; 30(3):657. PubMed ID: 23864249
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of combined androgen blockade with zoledronic acid treatment in prostate cancer with bone metastasis: the ZABTON-PC (zoledronic acid/androgen blockade trial on prostate cancer) study.
Ueno S; Mizokami A; Fukagai T; Fujimoto N; Oh-Oka H; Kondo Y; Arai G; Ide H; Horie S; Ueki O; Kawaguchi K; Shimamura M; Orito M; Ishida T; Ikeda D; Namiki M
Anticancer Res; 2013 Sep; 33(9):3837-44. PubMed ID: 24023317
[TBL] [Abstract][Full Text] [Related]
10. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.
Fizazi K; Carducci M; Smith M; Damião R; Brown J; Karsh L; Milecki P; Shore N; Rader M; Wang H; Jiang Q; Tadros S; Dansey R; Goessl C
Lancet; 2011 Mar; 377(9768):813-22. PubMed ID: 21353695
[TBL] [Abstract][Full Text] [Related]
11. Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases.
Xie J; Namjoshi M; Wu EQ; Parikh K; Diener M; Yu AP; Guo A; Culver KW
J Manag Care Pharm; 2011 Oct; 17(8):621-43. PubMed ID: 21942303
[TBL] [Abstract][Full Text] [Related]
12. Analysis of the Mechanism and Safety of Bisphosphonates in Patients with Lung Cancer and Bone Metastases.
Zhang G; Gong H; Xu H
Comput Math Methods Med; 2021; 2021():5343104. PubMed ID: 34938354
[TBL] [Abstract][Full Text] [Related]
13. Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial.
Himelstein AL; Foster JC; Khatcheressian JL; Roberts JD; Seisler DK; Novotny PJ; Qin R; Go RS; Grubbs SS; O'Connor T; Velasco MR; Weckstein D; O'Mara A; Loprinzi CL; Shapiro CL
JAMA; 2017 Jan; 317(1):48-58. PubMed ID: 28030702
[TBL] [Abstract][Full Text] [Related]
14. [Clinical application of zoledronic acid combined with vitamin K2 in percutaneous vertebroplasty for multi-segment osteoporotic vertebral compression fractures].
Huang Y; Wu D
Zhongguo Gu Shang; 2020 Sep; 33(9):820-6. PubMed ID: 32959568
[TBL] [Abstract][Full Text] [Related]
15. Antiresorptive agent-related osteonecrosis of the jaw in prostate cancer patients with bone metastasis treated with bone-modifying agents.
Nakai Y; Kanaki T; Yamamoto A; Tanaka R; Yamamoto Y; Nagahara A; Nakayama M; Kakimoto KI; Ishibashi M; Nishimura K
J Bone Miner Metab; 2021 Mar; 39(2):295-301. PubMed ID: 32886176
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness Analysis of Percutaneous Kyphoplasty Combined with Zoledronic Acid in Treatment of Primary Osteoporotic Vertebral Compression Fractures.
Huang ZF; Xiao SX; Liu K; Xiong W
Pain Physician; 2019 Jan; 22(1):63-68. PubMed ID: 30700069
[TBL] [Abstract][Full Text] [Related]
17. A prospective, multicenter, open-label trial of zoledronic acid in patients with hormone refractory prostate cancer.
Hong SJ; Cho KS; Cho HY; Ahn H; Kim CS; Chung BH
Yonsei Med J; 2007 Dec; 48(6):1001-8. PubMed ID: 18159593
[TBL] [Abstract][Full Text] [Related]
18. Clinical Efficacy Analysis of Percutaneous Kyphoplasty Combined with Zoledronic Acid in the Treatment and Prevention of Osteoporotic Vertebral Compression Fractures.
Liu B; Gan F; Ge Y; Yu H
J Invest Surg; 2018 Oct; 31(5):425-430. PubMed ID: 28829670
[TBL] [Abstract][Full Text] [Related]
19. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
Saad F; Gleason DM; Murray R; Tchekmedyian S; Venner P; Lacombe L; Chin JL; Vinholes JJ; Goas JA; Chen B;
J Natl Cancer Inst; 2002 Oct; 94(19):1458-68. PubMed ID: 12359855
[TBL] [Abstract][Full Text] [Related]
20. Zoledronic acid therapy impacts risk and frequency of skeletal complications and follow-up duration in prostate cancer patients with bone metastasis.
Hatoum HT; Lin SJ; Guo A; Lipton A; Smith MR
Curr Med Res Opin; 2011 Jan; 27(1):55-62. PubMed ID: 21083514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
